Number of Founded Organizations 1
CB Rank (Investor) 270,523
  • Gender Male

Brian M. Stoltz is currently a professor of chemistry at the California Institute of Technology. The primary focus of his research is chemical synthesis with an emphasis on expanding the scope of allylic alkylation for the preparation of complex molecules possessing unique structural, biological, and physical properties. His research involves the

total synthesis of natural products such as dragmacidin F and (–)-cyanthiwigin F, and development of synthetic reactions to access quaternary stereocenters. Specifically, he has focused on the allylic alkylation of enolates, developing an enantioselective variant in 2004.

Number of Current Jobs 1
Brian Stoltz is the Co-Founder at 1200 Pharma.
Brian Stoltz studied at Yale University.
FundOct 12, 2023
Alethia Venture Partners Raised a new fund: Alethia Opportunity Fund I ($50,000,000)